Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

Gabriel C. Caponetti, Bhavana J. Dave, Anamarija M. Perry, Lynette M. Smith, Smrati Jain, Paul N. Meyer, Martin Bast, Philip J. Bierman, Robert G. Bociek, Julie M. Vose, James O. Armitage, Patricia Aoun, Kai Fu, Timothy C. Greiner, Wing C. Chan, Warren G. Sanger, Dennis D. Weisenburger

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2-and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.

Original languageEnglish (US)
Pages (from-to)3082-3089
Number of pages8
JournalLeukemia and Lymphoma
Volume56
Issue number11
DOIs
StatePublished - Nov 2 2015

Keywords

  • BCL2
  • BCL6
  • Diffuse large B-cell lymphoma
  • MYC

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome'. Together they form a unique fingerprint.

  • Cite this